|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01652 FUSEN PHARM
Nominal 
0.260 0.000 (0.000%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 326,029 | -42.358% | 565,608 | 491,757 | 385,664 | 486,854 |
| Cost of Sales | (163,392) | -38.598% | (266,102) | (266,736) | (174,531) | (220,787) |
| Gross Profit | 162,637 | -45.698% | 299,506 | 225,021 | 211,133 | 266,067 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | (20,329) | (38,007) | (19,280) | (22,637) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (104,097) | 412.995% | (20,292) | (21,019) | (1,969) | 24,252 | |
| Profit / (Loss) before Taxation | (190,446) | 546.720% | (29,448) | (30,993) | 23,791 | 78,405 | |
| Taxation | 1,646 | -- | (6,847) | (3,661) | (7,178) | (15,737) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 17 | -5.556% | 18 | 49 | 32 | 7,463 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (188,783) | 420.393% | (36,277) | (34,605) | 16,645 | 70,131 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 18,838 | 113.027% | 8,843 | 15,725 | 7,097 | 7,730 |
| Depreciation & Amortisation | 41,711 | 16.518% | 35,798 | 34,161 | 23,785 | 22,457 |
| Directors' Emoluments | -- | -- | 5,769 | 2,580 | 2,655 | 2,259 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified (Modified Report) | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -26.000 | 420.000% | -5.000 | -5.000 | 2.000 | 9.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.910 | 0.910 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | 45.500% | 10.111% |
| Cash flow per share ($) | -- | -- | (0.098) | 0.146 | 0.062 | 0.195 |
| NBV per share ($) | 0.500 | -- | 0.751 | 0.810 | 0.855 | 0.852 |
| Remarks: | Real time quote last updated: 30/04/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -188,783,000 |
| %Change | 420.393% |
| EPS / (LPS) | RMB -0.260 |
| NBV Per Share (¥) | RMB 0.500 |